Mannkind Corp. share price logo

Mannkind Corp. Share Price

NASDAQ: MNKD

Small Cap

$2.54

+0.08

(+3.47%)

Live

as on

Mannkind Corp. Stock Performance

as on April 2, 2026 at 6:12 am IST

  • Day's Low

    Day's High

    $2.46
    $2.58
    downward going graph

    3.15%

    Downside

    1.57%

    Upside

    downward going graph

  • 52 Week's Low

    52 Week's High

    $2.23
    $6.51
    downward going graph

    12.20%

    Downside

    156.30%

    Upside

    downward going graph

Mannkind Corp. share price movements today

Previous Close
$2.45
Open
$2.47
Volume
2.7M
Day's Low - High
$2.46 - $2.58
52 Week Low - High
$2.23 - $6.51

Mannkind Corp. Historical Returns

1 Month Return
-25.3 %
3 Month Return
-56.79 %
1 Year Return
-50.51 %
3 Year Return
-40.24 %
5 Year Return
-41.03 %

Mannkind Corp. Stock Fundamentals & Key Indicators

Check Mannkind Corp. market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$730.2M

EPS (TTM)

0.0967

Dividend Yield

0.00%

Quarterly Earnings Growth YOY

-0.35%

PE Ratio (TTM)

118.5

Industry PE ratio

-4.164408945686901

PEG Ratio

4.3866

EBITDA

58.8M

Revenue (TTM)

349.0M

Profit Margin

1.68%

Return On Equity TTM

0.00%

Mannkind Corp. Stock Valuation

Track how Mannkind Corp. P/E has moved over time to understand its valuation trends.

Mannkind Corp. in the last 5 years

  • Overview

  • Trends

Lowest (-83.58x)

December 31, 2023

Industry (-4.16x)

April 1, 2026

Today (118.50x)

April 1, 2026

Highest (114.51x)

March 31, 2024

LowHigh

Today’s Price to Earnings Ratio: 118.50x

Mannkind Corp. vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of Mannkind Corp. with its industry peers.

Company
Analyst View
Market Cap
5 Years Return %PE RatioProfit Margin %
Mannkind Corp. image
Mannkind Corp.
BUY$730.2M-41.03%118.51.68%
Insmed Incorporated image
Insmed Incorporated
BUY$35.2B361.4%-16.34-210.54%
Alnylam Pharmaceuticals, Inc. image
Alnylam Pharmaceuticals, Inc.
BUY$41.9B133.32%135.088.45%
Vertex Pharmaceuticals Incorporated image
Vertex Pharmaceuticals Incorporated
BUY$112.6B109.6%28.9132.94%
Regeneron Pharmaceuticals, Inc. image
Regeneron Pharmaceuticals, Inc.
BUY$79.2B62.69%18.0531.41%

Stock Returns calculator for Mannkind Corp. Stock including INR - Dollar returns

The Mannkind Corp. stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Impact: The bonus return you make when the US Dollar rises against the Rupee; calculated on the full amount you walk away with, not just what you invested in.

Investment Value

₹1,00,000

  • 1Y

  • 3Y

  • 5Y

  • 7Y

  • 10Y

Mannkind Corp. investment value today

Current value as on today

₹55,939

Returns

-₹44,061

(-44.06%)

Returns from Mannkind Corp. Stock

-₹48,687 (-48.69%)

Dollar Impact

₹4,626 (+4.63%)

Analyst Recommendation on Mannkind Corp. Stock

Based on 12 analysts

BUY

83.33%

Buy

16.67%

Hold

0.00%

Sell

Based on 12 analysts, 83.33% of analysts recommend a 'BUY' rating for Mannkind Corp.. Average target price of $7.5

Mannkind Corp. Share Price Target

Get share price movements and forecasts by analysts on Mannkind Corp..

What analysts predicted

66.13%UPSIDE

Target Price

$7.5

Current Price

$2.54

Analyzed by

12 Analysts

Target

$7.50

Mannkind Corp. target price $7.5, a slight upside of 66.13% compared to current price of $2.54. According to 12 analysts rating.

Mannkind Corp. Stock’s Investor Sentiment and Interest

Search interest for Mannkind Corp. Stock has decreased by -3% in the last 30 days, reflecting a downward trend in search activity.

Time period: to

Change:-3% versus previous 30 day period

Mannkind Corp. Quarterly Profit & Loss

All numbers in Millions USD

Sep 2023
Dec 2023
Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Total Revenue
51
58
66
72
70
76
78
76
82
111
Gross Profit
36
40
47
52
52
57
60
55
61
87
Operating Income
5
7
16
16
12
26
22
5
18
-7
EBITDA
8
9
21
13
23
18
26
9
17
-2
Interest Expense
5
5
9
12
8
7
10
6
7
13
Depreciation
1
1
1
2
2
2
2
2
2
4
Income Before Tax
1
2
10
-1
12
8
13
0
7
-20
Income Tax Expense
5
1
0
0
1
1
0
0
0
-4
Net Income
1
1
10
-2
11
7
13
0
7
-15
Net Profit Margin
3.36%
2.40%
16.04%
-2.78%
16.48%
9.67%
16.79%
0.87%
9.72%
-14.25%

Mannkind Corp. Annual Profit & Loss

All numbers in Millions USD

Dec 2016
Dec 2017
Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Total Revenue
174
11
27
63
65
75
99
198
285
348
Gross Profit
124
-5
7
35
40
36
42
136
208
287
Operating Income
67
-108
-76
-44
-47
-47
-64
8
72
38
EBITDA
64
-102
-75
-38
-44
-61
-56
15
77
27
Interest Expense
18
13
9
10
9
16
24
25
37
13
Depreciation
-
3
2
2
3
5
9
8
9
12
Income Before Tax
125
-117
-86
-51
-57
-80
-87
-10
30
1
Income Tax Expense
13
0
0
7
0
10
24
1
2
-4
Net Income
125
-117
-86
-51
-57
-80
-87
-11
27
5
Net Profit Margin
71.91%
-999.00%
-312.20%
-82.34%
-87.87%
-107.27%
-87.60%
-6.00%
9.66%
1.68%

Mannkind Corp. Quarterly Cash Flow

All numbers in Millions USD

Dec 2023
Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Net Income
1
10
-2
11
7
13
0
7
-15
Operating Cash Flow
21
6
3
9
22
-6
8
23
-7
Investing Cash Flow
-7
-48
-55
-41
48
5
6
-25
-291
Financing Cash Flow
141
-3
-44
-2
-86
1
-5
71
247
Change in Cash
155
-45
-95
-34
-16
0
9
70
-52

Mannkind Corp. Annual Cash Flow

All numbers in Millions USD

Dec 2017
Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Net Income
-117
-86
-51
-57
-80
-87
-11
27
5
Operating Cash Flow
-64
-37
-88
-28
-61
-80
34
42
18
Investing Cash Flow
16
0
-22
15
-151
4
-1
-96
-304
Financing Cash Flow
73
61
69
49
270
21
136
-137
315
Change in Cash
25
23
-41
36
57
-54
168
-191
28

Global Institutional Holdings in Mannkind Corp.

Funds
Holdings
Geode Capital Management, LLC
2.39%
UBS Group AG
1.69%
Frazier Life Sciences Management, L.P.
1.37%
180 WEALTH ADVISORS, LLC
0.96%
Charles Schwab Investment Management Inc
0.83%
See all

Mannkind Corp. News & Key Events

  • img

    Today's Timeline - 01 December

    Mon, 06:35 PM

    -

    MannKind's FUROSCIX ReadyFlow Autoinjector sNDA accepted by FDA for review, targeting chronic heart failure and kidney disease treatment.

Insights on Mannkind Corp.

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

  • imgPOSITIVE IMPACT

    Price Rise

    img

    In the last 7 days, MNKD stock has moved up by 7.5%

  • imgPOSITIVE IMPACT

    Revenue Rich

    img

    Revenue is up for the last 3 quarters, 76.52M → 111.95M (in $), with an average increase of 16.7% per quarter

  • imgNO EFFECT

    Against Peers

    img

    In the last 3 years, Insmed Incorporated has given 859.1% return, outperforming this stock by 899.3%

  • imgNO EFFECT

    Against Peers

    img

    In the last 1 year, Insmed Incorporated has given 127.1% return, outperforming this stock by 177.6%

  • imgNEGATIVE IMPACT

    Profit Down

    img

    Netprofit is down for the last 2 quarters, 7.98M → -15.94M (in $), with an average decrease of 299.7% per quarter

About Mannkind Corp.

mannkind corporation (nasdaq: mnkd) focuses on the discovery, development and commercialization of therapeutic products for patients with diseases such as diabetes and cancer. in addition, mannkind is applying our novel technologies and services to support partner development efforts.
OrganisationMannkind Corp.
Headquarters1 Casper Street, Danbury, CT, United States, 06810
IndustryHealth Technology
CEODr. Michael E. Castagna Pharm.D.
E-voting on sharesClick here to vote

Key Management of Mannkind Corp.

Name

Title

Dr. Stuart A. Tross Ph.D.

Chief People & Workplace Officer

Mr. Dominic Marasco R.Ph.

President of Endocrine Business Unit

Dr. Ajay Ahuja M.B.A., M.D.

Executive VP & Chief Medical Officer

Dr. Michael E. Castagna Pharm.D.

CEO & Director

Mr. Christopher B. Prentiss M.B.A.

Chief Financial Officer

Dr. David B. Thomson J.D., Ph.D.

Executive VP, General Counsel & Secretary

Mr. Sanjay Singh M.B.A.

Executive Vice President of Technical Operations

FAQs

What is Mannkind Corp. share price today?

Mannkind Corp. share price today is $2.54 as on . Mannkind Corp. share today touched a day high of $2.58 and a low of $2.46.

What is the 52 week high and 52 week low for Mannkind Corp. share?

Mannkind Corp. share touched a 52 week high of $6.51 on and a 52 week low of $2.23 on . Mannkind Corp. stock price today i.e. is trending at $2.54,which is 60.98% down from its 52 week high and 13.90% up from its 52 week low.

What is Mannkind Corp.'s market capitalisation today?

Mannkind Corp. market capitalisation is $0.00T as on .

How to invest in Mannkind Corp. Stock (MNKD) from India?

  1. Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
  2. Step 2: Search for Mannkind Corp. on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Mannkind Corp. Shares that will get you 0.5906 shares as per Mannkind Corp. share price of $2.54 per share as on April 2, 2026 at 12:42 am IST.

What is the minimum amount required to buy Mannkind Corp. Stock (MNKD) from India?

Indian investors can start investing in Mannkind Corp. (MNKD) shares with as little as ₹93.295 or $1 (as of ) using the INDmoney app.
For example: If you want to invest $10 or ₹932.95 in Mannkind Corp. stock (as per the Rupee-Dollar exchange rate as on ). Based on Mannkind Corp. share’s latest price of $2.54 as on April 2, 2026 at 12:42 am IST, you will get 3.9370 shares of Mannkind Corp.. Learn more about fractional shares .

What are the returns that Mannkind Corp. has given to Indian investors in the last 5 years?

Mannkind Corp. stock has given -41.03% share price returns and 28.7% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?